Provention Bio Inc. (PRVB): Why insiders taking interest in this stock

0
39

Provention Bio Inc. (NASDAQ:PRVB) changes shares on Tuesday trading session, with a change of 0.09% or $0.01 shares. The trading starts at $11.70 and closed at $11.23 throughout the day. The trading session low price was $10.88 and day high was $11.70 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 0.53 million while its average volume is 1.06M. In other hand, the PRVB market cap reached to $630.90M.

On June 18, 2020, BRIEF-Provention Bio Announces Pricing Of 6.60 Mln Common Shares At $14.50 Per Share. According to the news reported on Reuters, * PROVENTION BIO ANNOUNCES PRICING OF $95.7 MILLION PUBLIC OFFERING OF COMMON STOCK

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 5.34% and down -17.11% for month. Its quarterly performance was -3.52% below, while its half year performance is down -25.02%. PRVB yearly performance stood at positive 13.19% and fall -24.56% for year-to-date. Current recommendation for Provention Bio Inc. is 1.70.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. PRVB EPS (TTM) for 12-month is -1.05. EPS for this year is -34.50%, while for the next year its value is -1.54. Its EPS Q/Q reached 10.20%.

Perceptive Advisors Llc, Vanguard Group, Inc. (The) and Johnson & Johnson Innovation – JJDC, Inc. are the top three holders in Provention Bio Inc. (PRVB) stock. On Mar 30, 2020, Perceptive Advisors Llc has 3.01 million shares which valued 27.71 million. On Mar 30, 2020, Vanguard Group, Inc. (The) owned 1.41 million shares which valued at 13.0 million. On Mar 30, 2020, Johnson & Johnson Innovation – JJDC, Inc. has a total of 1.12 million shares which valued at 10.35 million. In the end, Johnson & Johnson Innovation – JJDC, Inc. have 2.32% shares outstanding of Provention Bio Inc. (PRVB) on Mar 30, 2020. The insider ownership moved to 4.70% and institutional holding shifted to 22.70%.

The company posted an EPS (TTM) of -1.05. According to the most recent quarter report on (Jun 2020), 7 analysts estimated an average EPS of -0.28, while -0.32 EPS posted a year ago period. Analyst Estimated EPS for PRVB published in the report was -$0.31 – -$0.22 during the same period. Comparing with last year, the average estimated EPS was -0.32 which is lower than -0.26 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for PRVB fall -5.09% for period of 200 days. SMA for 50 days was -16.45% which is showing red signal, while SMA-20 was -6.15%. The moving average value for Provention Bio Inc. (PRVB) is 12.42 and 13.22 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in PRVB stock. On Jun 24, Leon Francisco, Chief Scientific Officer, bought 2,000 trading shares at the cost of $15.43, which valued at 30862.0. On Mar 19, Leon Francisco, Chief Scientific Officer, bought 10,000 shares at the cost of $5.92, with total shares of 2,563,450. On Mar 19, Hoitt Jason, Chief Commercial Officer, bought 4,500 shares at the cost of 5.43. After this transaction, Hoitt Jason total shares reached to 4,500 which valued at 24435.0.